ABVC BIOPHARMA, INC.

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

1.00 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Key numbers

Fiscal year 2024, ended 31 Dec 2024, as filed

Revenue

$509.59K

Net income

$4.90M

Free cash flow

$1.81M

Gross margin

99.9%

Operating margin

-923.3%

Net margin

-962.1%

Return on equity

-399.9%

Return on capital

-275.2%

Debt to equity

0.10

Revenue growth, 1 yr

234.3%

Revenue growth, 5 yr

-6.2% a year

Revenue and profit

Fiscal years, as filed with the SEC · point at a year for the detail

Full statements →

RevenueNet incomeLoss

Latest insider transactions

From Form 4, most recent first

All of them →

Date	Insider	Type	Value	Of own stake
11 May 2010	Nirta Joseph Director	Bought	$1.50K	opened
22 Mar 2010	Nirta Joseph Director	Bought	$520.00	opened
13 Nov 2009	Smith J.B. Director	Bought	$35.71B	4.5%
31 Aug 2009	Smith J.B. Director	Bought	$9.62B	1.1%
10 Jun 2009	Smith J.B. Director	Bought	$400.00K	6.3%
2 Jun 2009	Smith J.B. Director	Bought	$4.63M	4.1%

Clue Score

How it works

38out of 100

Profitability 20

Financial strength 38

Growth 48

Insiders 50

Strongest on insiders (50), weakest on profitability (20). A score of the business, not of the price.

What insiders did

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan

Every insider, every trade →

Profile

Sector: Health care
Industry: Pharmaceutical Preparations
Country: United States
SEC filings: EDGAR →